The Management Board of Selvita S.A. with its registered office in Krakow (“Company”, “Selvita”) hereby announces that on June 29th, 2023 the Company has entered into a Statement of Work with a total value of EUR 1,856,213 (PLN 8,278,709.98 converted at the exchange rate of EUR 1 = PLN 4,46) (“Statement of Work”) under a Framework Agreement entered into on March 21st, 2022 with an early stage drug discovery company with its registered office in Italy (“Customer”).

Under the Statement of Work, the Company will provide FTE-based integrated drug discovery support for a period of 12 months. In addition, the Statement of Work provides for an option for the Customer to extend the scope of services, which would increase the total value of the Statement of work to EUR 2,180,213.

Taking into account the value of the Statement of Work, the Management Board of Selvita considers it important for the implementation of the Selvita Group’s long-term plans aimed at building a strong position as a leading service provider in the area of drug discovery project support.

Disclaimer: This English language translation has been prepared solely for the convenience of English speaking readers. Despite all the efforts devoted to this translation, certain discrepancies, omissions or approximations may exist. In case of any differences between the Polish and the English versions, the Polish version shall prevail. Selvita S.A., its representatives and employees decline all responsibility in this regard.

Legal basis: Art. 17.1 MAR

Representatives of the Company:     

  • Bogusław Sieczkowski – President of the Management Board
  • Miłosz Gruca – Vice-President of the Management Board